4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · IEX Real-Time Price · USD
25.34
-0.30 (-1.17%)
At close: May 17, 2024, 4:00 PM
24.72
-0.62 (-2.45%)
After-hours: May 17, 2024, 7:37 PM EDT
4D Molecular Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for FDMT stock have an average target of 46.56, with a low estimate of 31 and a high estimate of 81. The average target predicts an increase of 83.74% from the current stock price of 25.34.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for FDMT stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 4 | 4 | 5 | 5 |
| Buy | 2 | 3 | 3 | 3 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 8 | 8 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $36 | Strong Buy | Reiterates | $36 | +42.07% | May 13, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $35 → $40 | Buy | Maintains | $35 → $40 | +57.85% | Apr 15, 2024 |
| Barclays | Barclays | Buy Initiates $45 | Buy | Initiates | $45 | +77.58% | Apr 15, 2024 |
| BMO Capital | BMO Capital | Buy Maintains $70 → $63 | Buy | Maintains | $70 → $63 | +148.62% | Apr 1, 2024 |
| Jefferies | Jefferies | Strong Buy Maintains $30 → $58 | Strong Buy | Maintains | $30 → $58 | +128.89% | Apr 1, 2024 |
Financial Forecast
Revenue This Year
5.87M
from 20.72M
Decreased by -71.66%
Revenue Next Year
7.61M
from 5.87M
Increased by 29.55%
EPS This Year
-3.14
from -2.58
EPS Next Year
-3.47
from -3.14
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 22.1M | 17.7M | 2.1M | 225.8M | 871.5M |
| Avg | 5.9M | 7.6M | 2.0M | 60.9M | 229.0M |
| Low | n/a | n/a | 1.9M | 1.8M | 10.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 6.4% | 202.2% | -72.4% | 10,993.4% | 1,330.7% |
| Avg | -71.7% | 29.5% | -73.2% | 2,893.4% | 275.9% |
| Low | - | - | -74.4% | -9.2% | -82.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.03 | -1.38 | -3.98 | -1.12 | 3.28 |
| Avg | -3.14 | -3.47 | -4.67 | -3.39 | -2.61 |
| Low | -3.22 | -4.41 | -5.25 | -4.23 | -5.55 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.